Longitudinal Patient‐Reported Voice Quality in Early‐Stage Glottic Cancer
Otolaryngology–Head and Neck Surgery · 2023
DOI: 10.1002/ohn.263 ↗At a glance
Beobachtungsstudie in Otolaryngology–Head and Neck Surgery, 2023. Written by Maarten C Dorr and 10 co-authors. Institution: Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlan…. Major MEDLINE topics: Laryngeal Neoplasms, Laser Therapy. Cited 7 times so far (Crossref); 56 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Objective
Patient‐reported voice quality is an important outcome during counseling in early‐stage glottic cancer. However, there is a paucity of adequate longitudinal studies concerning voice outcomes. This study aimed to investigate longitudinal trajectories for patient‐reported voice quality and associated risk factors for treatment modalities such as transoral CO 2 laser microsurgery, single vocal cord irradiation, and local radiotherapy. Study Design A longitudinal observational cohort study.
Setting
Tertiary cancer center.
Methods
Patients treated for Tcis‐T1b, N0M0 glottic cancer were included in this study (N = 294). The Voice Handicap Index was obtained at baseline and during follow‐up (N = 1944). Mixed‐effects models were used for investigating the different trajectories for patient‐reported voice quality.
Results
The mean follow‐up duration was 43.4 (SD 21.5) months. Patients received transoral CO 2 laser microsurgery (57.8%), single vocal cord irradiation (24.5%), or local radiotherapy (17.5%). A steeper improvement during the first year after treatment for single vocal cord irradiation (−15.7) and local radiotherapy (−12.4) was seen, compared with a more stable trajectory for laser surgery (−6.1). All treatment modalities showed equivalent outcomes during long‐term follow‐up. Associated risk factors for different longitudinal trajectories were age, tumor stage, and comorbidity.
Conclusion
Longitudinal patient‐reported voice quality after treatment for early‐stage glottic cancer is heterogeneous and nonlinear. Most improvement is seen during the first year of follow‐up and differs between treatment modalities. No clinically significant differences in long‐term trajectories were found. Insight into longitudinal trajectories can enhance individual patient counseling and provide the foundation for an individualized dynamic prediction model.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Department of Biostatistics and Epidemiology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
ORCID profiles: Maarten C Dorr
Cite
APA
Dorr, M. C., Sewnaik, A., Andrinopoulou, E., Berzenji, D., Dronkers, E. A. C., Bernard, S. E., Hoesseini, A., Tans, L., Rizopoulos, D., Baatenburg de Jong, R. J., & Offerman, M. P. J. (2023). Longitudinal Patient‐Reported Voice Quality in Early‐Stage Glottic Cancer. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.263
Vancouver
Dorr MC, Sewnaik A, Andrinopoulou E, Berzenji D, Dronkers EAC, Bernard SE, et al. Longitudinal Patient‐Reported Voice Quality in Early‐Stage Glottic Cancer. Otolaryngology–Head and Neck Surgery. 2023. doi:10.1002/ohn.263
BibTeX
@article{Dorr2023,
author = {Dorr, Maarten C and Sewnaik, Aniel and Andrinopoulou, Elrozy and Berzenji, Diako and Dronkers, Emilie A C and Bernard, Simone E and Hoesseini, Arta and Tans, Lisa and Rizopoulos, Dimitris and Baatenburg de Jong, Robert J and Offerman, Marinella P J},
title = {Longitudinal Patient‐Reported Voice Quality in Early‐Stage Glottic Cancer},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2023},
doi = {10.1002/ohn.263}
}
EUVIMED